Anika Therapeutics, Inc. (ANIK) stock
Close on Nov 12, 2026Market cap $184.82MP/E –Yield –
Anika Therapeutics, Inc. grew revenue 9.4% to $123.43M over the twelve months to Sep 30, 2026. Free cash flow was $2.30M, up 254.2% from a year earlier. At the latest close the market valued the company at $184.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $184.82M
- P/E ratio
- –
- Price to sales
- 1.50
- Price to book
- 1.34
- Dividend yield
- –
- Free cash flow yield
- 1.24%
Fundamentals
- Revenue
- $123.43M
- Net income
- -$1.77M
- EPS, diluted
- -$0.13
- Free cash flow
- $2.30M
- Book value per share
- $10.28
- Diluted shares
- 13M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $13.95
- Open
- $13.80
- Day's range
- $13.65 – $14.21
- Volume
- 93,809
- Average volume (20 days)
- 121,019
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 0.86
- 52-week range
- $9.01 – $22.88
- RSI (14 days)
- 24.7
- Volatility (1 year)
- 57.0%
- Relative volume
- 0.89×
- WACC
- 9.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANIK | S&P 500 | Difference | ANIK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.5% | -2.7% | −29.8 pts | ||
| 3 months | -37.3% | -1.7% | −35.6 pts | ||
| Year to date | +43.7% | +11.9% | +31.8 pts | ||
| 1 year | +36.7% | +12.0% | +24.7 pts | ||
| 3 years | -31.0% | +78.2% | −109.2 pts | -11.6% | +21.2% |
| 5 years | -64.4% | +73.2% | −137.6 pts | -18.6% | +11.6% |
| 10 years | -69.7% | +309.6% | −379.3 pts | -11.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Anika Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Anika Therapeutics
Surgical & Medical Instruments & Apparatus
Anika Therapeutics, Inc. develops and commercializes medical therapies focused on osteoarthritis pain management and regenerative solutions for early intervention orthopedics. Utilizing proprietary hyaluronic acid technology, the company offers pain relief injections such as Orthovisc, Monovisc, and Cingal, alongside regenerative orthopedic implants and bone substitutes including the Integrity system, Hyalofast, and Tactoset. It also supplies non-orthopedic legacy lines, comprising ophthalmic aids, anti-adhesion barriers, and equine treatments. Anika serves healthcare providers across office practices, hospital operating rooms, and ambulatory surgery centers through direct sales, commercial partnerships, and third-party distributors.
Company profile, executives and historyAnika Therapeutics stock: common questions
What is Anika Therapeutics's stock price?
ANIK closed at $13.81 on Nov 12, 2026, down 1.00% on the day. Over the past 52 weeks it traded between $9.01 and $22.88.
What is Anika Therapeutics's market cap?
Anika Therapeutics was worth $184.82M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ANIK's P/E ratio?
Anika Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.13), so it has no meaningful P/E ratio.
How much revenue does Anika Therapeutics make?
Anika Therapeutics reported revenue of $123.43M for the twelve months to Sep 30, 2026, up 9.4% from a year earlier.
Does Anika Therapeutics pay a dividend?
No. Anika Therapeutics has not paid a cash dividend over the last twelve months.
When does Anika Therapeutics report earnings next?
Anika Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ANIK stock performed over the past year?
Including dividends, ANIK returned +36.7% over the past year, against +12.0% for the S&P 500.
How many ANIK shares are sold short?
0M shares were sold short at the latest FINRA report, 2.91% of the float, or 3.1 days of average trading volume.
Who are Anika Therapeutics's competitors?
Companies most similar to Anika Therapeutics by business, industry and size include XTNT, BVS, TELA, RCEL, SIBN.
See a number that looks wrong?